$FLGT News

Fulgent Genetics' FID-007 Plus Cetuximab Shows 60% Response Rate And 7.2-Month Median PFS In Phase 2 Head And Neck Cancer Study With Favorable Safety Profile

Piper Sandler Reiterates Neutral on Fulgent Genetics, Lowers Price Target to $15

Fulgent Genetics (NASDAQ:FLGT) Shares Dip Premarket After Q1 Earnings Miss Despite Revenue Beat

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

Full Transcript: Fulgent Genetics Q1 2026 Earnings Call

Fulgent Genetics: A Major Market Misconception

Fulgent Genetics, Inc. 2025 Q4 - Results - Earnings Call Presentation

Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript

Fulgent Genetics (NASDAQ:FLGT) Shares Plunge on Weak 2026 Outlook After Mixed Q4

Fulgent Genetics shares are trading lower after the company reported mixed Q4 financial results. The company also issued FY26 guidance below estimates.

Fulgent Genetics shares are trading lower after the company reported mixed Q4 financial results. The company also issued FY26 guidance below estimates.

Fulgent Genetics Sees FY2026 Adj EPS $(1.45) vs $(0.32) Est; Sees Sales $350.000M vs $356.333M Est

Fulgent Genetics Q4 Earnings Assessment

Fulgent Genetics Q4 Adj. EPS $0.16 Beats $0.03 Estimate, Sales $83.336M Miss $85.381M Estimate

Earnings Preview: Fulgent Genetics

Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock

New Strong Buy Stocks for January 12th

Fulgent Genetics to buy Bako Diagnostics assets and StrataDx

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx